Currently out of the existing stock ratings of Debjit Chattopadhyay, 204 are a BUY (90.67%), 21 are a HOLD (9.33%).

Debjit Chattopadhyay

Work Performance Price Targets & Ratings Chart

Analyst Debjit Chattopadhyay, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 49.34% that have a potential upside of 38.95% achieved within 241 days. Previously, Debjit Chattopadhyay worked at ROTH MKM, JANNEY, HC WAINWRIGHT.

Debjit Chattopadhyay’s has documented 440 price targets and ratings displayed on 47 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on RZLT, Rezolute at 15-Jun-2026.

Wall Street Analyst Debjit Chattopadhyay

Analyst best performing recommendations are on PEPG (PEPGEN LTD).
The best stock recommendation documented was for PEPG (PEPGEN LTD) at 9/9/2025. The price target of $6 was fulfilled within 77 days with a profit of $4.52 (305.41%) receiving and performance score of 39.66.

Average potential price target upside

QURE Uniqure NV SRPT Sarepta Therapeutics BEAM Beam Therapeutics  BLUE Bluebird bio CLVS Clovis Oncology IONS Ionis Pharmaceuticals NTLA Intellia Therapeutics TSHA Taysha Gene Therapies  PASG Passage Bio BMRN Biomarin Pharmaceutical KRYS Krystal Biotech VRTX Vertex Pharmaceuticals CNTA Centessa Pharmaceuticals PLC ADR ALLO Allogene Therapeutics AUTL Autolus Therapeutics Ltd BOLD Audentes Therapeutics GBT Global Blood Therapeutics GLPG Galapagos NV ADR HARP Harpoon Therapeutics IMGN ImmunoGen JNCE Jounce Therapeutics SLNO Soleno Therapeutics MGNX MacroGenics MRSN Mersana Therapeutics VYGR Voyager Therapeutics NKTR Nektar Therapeutics DTIL Precision BioSciences BCYC Bicycle Therapeutics Ltd BNTC Benitec Biopharma Ltd ADR DYN Dyne Therapeutics  FATE Fate Therapeutics FOLD Amicus Therapeutics RZLT Rezolute WVE Wave Life Sciences Ltd PRME Prime Medicine, Common Stock SMMT Summit Therapeutics PLC DARE Dare Bioscience NEO NeoGenomics RARE Ultragenyx ZYME Zymeworks Common Stock PEPG PepGen Ltd AGIO Agios Pharm ALNY Alnylam Pharmaceuticals AVRO AVROBIO BL Blackline NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares PHVS Pharvaris BV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Jul-2026

$75

$31.37 (71.90%)

$60

4 days ago
(30-Jul-2026)

4/8 (50%)

$32.81 (77.77%)

88

Buy Since 30-Jul-2026

$60

$16.37 (37.52%)

$65

4 days ago
(30-Jul-2026)

5/8 (62.5%)

$17.81 (42.21%)

784

Buy Since 25-Jun-2026

$68

$24.37 (55.86%)

$35

1 months 9 days ago
(25-Jun-2026)

6/7 (85.71%)

$18.9 (38.49%)

87

Buy Since 15-Nov-2018

$70

$26.37 (60.44%)

$68

1 months 16 days ago
(18-Jun-2026)

6/7 (85.71%)

$23.71 (51.22%)

668

Buy Since 18-Jun-2026

$65

$21.37 (48.98%)

$35

1 months 16 days ago
(18-Jun-2026)

9/10 (90%)

$18.71 (40.42%)

764

Show more analysts

Please expand the browser size to see the chart

Which stock is Debjit Chattopadhyay is most bullish on?

Potential upside of $25.98 has been obtained for BMRN (BIOMARIN PHARMACEUTICAL)

Which stock is Debjit Chattopadhyay is most reserved on?

Potential downside of -$57.12 has been obtained for KRYS (KRYSTAL BIOTECH)

What Year was the first public recommendation made by Debjit Chattopadhyay?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?